Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurology and Therapy
Published in: Neurology and Therapy 6/2023

Open Access 16-10-2023 | Alzheimer's Disease | ORIGINAL RESEARCH

Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study

Authors: Yuanyuan Gao, Dan Su, Zhouya Xue, Lin Ji, Shu Wang

Published in: Neurology and Therapy | Issue 6/2023

Login to get access

Abstract

Introduction

Serum neurofilament light chain (sNfL) is an emerging biomarker of neuronal damage in several neurological disorders. Its association with cognitive function in the general US population aged 60 years and above is unknown. The aim of this study was to investigate the correlation between sNfL and cognitive function in the general US population aged 60 and above.

Methods

The data were obtained from the 2013–2014 National Health and Nutrition Examination Survey (NHANES), which include 506 individuals aged 60 or older who met our search criteria. In our study, sNfL levels were divided into two groups based on dichotomization (19.0 pg/mL). After adjusting for multiple covariates, it was found that the high sNfL group (≥ 19.0 pg/mL) had lower cognitive performance than the low sNfL group (< 19.0 pg/mL). This relationship was also stable in subgroup analysis.

Conclusion

In this sample of an American elderly population, higher sNfL levels are correlated with lower cognitive performance. Our findings suggest that sNfL may become a potential screening tool for early prediction and confirmation of cognitive damage.
Literature
1.
2.
Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157–72.PubMedCrossRef
3.
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–91.PubMedCrossRef
4.
5.
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.PubMedPubMedCentralCrossRef
6.
7.
8.
Li RX, Ma YH, Tan L, Yu JT. Prospective biomarkers of Alzheimer’s disease: a systematic review and meta-analysis. Ageing Res Rev. 2022;81: 101699.PubMedCrossRef
9.
Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, et al. Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011;7(2):127–32.PubMedCrossRef
10.
Zetterberg H, Bendlin BB. Biomarkers for Alzheimer’s disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry. 2021;26(1):296–308.PubMedCrossRef
11.
Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer’s disease concord with amyloid-beta PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470–81.PubMedPubMedCentralCrossRef
12.
Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.PubMedCrossRef
13.
Gaetani L, Paolini Paoletti F, Bellomo G, Mancini A, Simoni S, Di Filippo M, et al. CSF and blood biomarkers in neuroinflammatory and neurodegenerative diseases: implications for treatment. Trends Pharmacol Sci. 2020;41(12):1023–37.PubMedCrossRef
14.
Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791–9.PubMedPubMedCentralCrossRef
15.
Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84.PubMedCrossRef
16.
Lin YS, Lee WJ, Wang SJ, Fuh JL. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep. 2018;8(1):17368.PubMedPubMedCentralCrossRef
17.
Chatterjee P, Cheong YJ, Bhatnagar A, Goozee K, Wu Y, McKay M, et al. Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. J Neurochem. 2020;159(2):389–402.PubMedCrossRef
18.
Ramani S, Berard JA, Walker LAS. The relationship between neurofilament light chain and cognition in neurological disorders: a scoping review. J Neurol Sci. 2021;420:117229.PubMedCrossRef
19.
Yilmaz A, Blennow K, Hagberg L, Nilsson S, Price RW, Schouten J, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017;17(8):761–70.PubMedCrossRef
20.
Dzierzewski JM, Dautovich N, Ravyts S. Sleep and cognition in older adults. Sleep Med Clin. 2018;13(1):93–106.PubMedCrossRef
21.
Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer’s Disease Neuroimaging I. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557–66.PubMedPubMedCentralCrossRef
22.
Disanto G, Barro C, Benkert P, Naegelin Y, Schädelin S, Giardiello A, et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857–70.PubMedPubMedCentralCrossRef
23.
Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the Digit Symbol Substitution Test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21(2):97–107.PubMedCrossRef
24.
Hoyer WJ, Stawski RS, Wasylyshyn C, Verhaeghen P. Adult age and digit symbol substitution performance: a meta-analysis. Psychol Aging. 2004;19(1):211–4.PubMedCrossRef
25.
Proust-Lima C, Amieva H, Dartigues JF, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol. 2007;165(3):344–50.PubMedCrossRef
26.
Peeri NC, Egan KM, Chai W, Tao M-H. Association of magnesium intake and vitamin D status with cognitive function in older adults: an analysis of US National Health and Nutrition Examination Survey (NHANES) 2011 to 2014. Eur J Nutr. 2020;60(1):465–74.PubMedPubMedCentralCrossRef
27.
Baker ML, Wang JJ, Rogers S, Klein R, Kuller LH, Larsen EK, Wong TY. Early age-related macular degeneration, cognitive function, and dementia: the Cardiovascular Health Study. Arch Ophthalmol. 2009;127(5):667–73.PubMedPubMedCentralCrossRef
28.
Rosano C, Newman AB, Katz R, Hirsch CH, Kuller LH. Association between lower digit symbol substitution test score and slower gait and greater risk of mortality and of developing incident disability in well-functioning older adults. J Am Geriatr Soc. 2008;56(9):1618–25.PubMedPubMedCentralCrossRef
29.
Swindell WR, Cummings SR, Sanders JL, Caserotti P, Rosano C, Satterfield S, et al. Data mining identifies digit symbol substitution test score and serum cystatin c as dominant predictors of mortality in older men and women. Rejuvenation Res. 2012;15(4):405–13.PubMedPubMedCentralCrossRef
30.
Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42(5):484–91.PubMedCrossRef
31.
Morgenstern J, Groener JB, Jende JME, Kurz FT, Strom A, Göpfert J, et al. Neuron-specific biomarkers predict hypo- and hyperalgesia in individuals with diabetic peripheral neuropathy. Diabetologia. 2021;64(12):2843–55.PubMedPubMedCentralCrossRef
32.
Ziegler D, Papanas N, Schnell O, Nguyen BDT, Nguyen KT, Kulkantrakorn K, et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2020;12(4):464–75.PubMedPubMedCentralCrossRef
33.
Kim S-H, Choi MK, Park NY, Hyun J-W, Lee MY, Kim HJ, et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep. 2020;10(1).
34.
van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2019;24(2):187–94.PubMedCrossRef
35.
Xue M, Xu W, Ou Y-N, Cao X-P, Tan M-S, Tan L, et al. Diabetes mellitus and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 144 prospective studies. Ageing Res Rev. 2019;55.
36.
Giacomucci G, Mazzeo S, Bagnoli S, Ingannato A, Leccese D, Berti V, et al. Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022;269(8):4270–80.PubMedPubMedCentralCrossRef
37.
He L, Morley JE, Aggarwal G, Nguyen AD, Vellas B, de Souto BP, et al. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults. Sci Rep. 2021;11(1):13394.PubMedPubMedCentralCrossRef
38.
Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, et al. Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimers Dement (Amst). 2019;11:700–9.PubMedCrossRef
39.
Ciardullo S, Muraca E, Bianconi E, Ronchetti C, Cannistraci R, Rossi L, et al. Serum neurofilament light chain levels are associated with all-cause mortality in the general US population. J Neurol. 2023.
40.
Kurucu H, Colom-Cadena M, Davies C, Wilkins L, King D, Rose J, et al. Inhibitory synapse loss and accumulation of amyloid beta in inhibitory presynaptic terminals in Alzheimer’s disease. Eur J Neurol. 2022;29(5):1311–23.PubMedCrossRef
41.
42.
Fathy YY, Jonkman LE, Bol JJ, Timmermans E, Jonker AJ, Rozemuller AJM, et al. Axonal degeneration in the anterior insular cortex is associated with Alzheimer’s co-pathology in Parkinson’s disease and dementia with Lewy bodies. Transl Neurodegener. 2022;11(1):52.PubMedPubMedCentralCrossRef
43.
O’Keeffe GW, Sullivan AM. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson’s disease. Parkinsonism Relat Disord. 2018;56:9–15.PubMedCrossRef
44.
45.
Dhana A, DeCarli C, Dhana K, Desai P, Wilson RS, Evans DA, et al. White matter hyperintensity, neurofilament light chain, and cognitive decline. Ann Clin Transl Neurol. 2023;10(3):321–7.PubMedCrossRef
46.
Nixon RA, Paskevich PA, Sihag RK, Thayer CY. Phosphorylation on carboxyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo influences on regional neurofilament accumulation, interneurofilament spacing, and axon caliber. J Cell Biol. 1994;126(4):1031–46.PubMedCrossRef
47.
Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019;25(2):277–83.PubMedPubMedCentralCrossRef
Metadata
Title
Association Between Serum Neurofilament Light Chain and Cognitive Performance Among Older Adults in the United States: A Cross-Sectional Study
Authors
Yuanyuan Gao
Dan Su
Zhouya Xue
Lin Ji
Shu Wang
Publication date
16-10-2023
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 6/2023
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-023-00555-9

Other articles of this Issue 6/2023

Neurology and Therapy 6/2023 Go to the issue

GUIDELINES

Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE

ORIGINAL RESEARCH

Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

COMMENTARY

Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary

ORIGINAL RESEARCH

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis

ORIGINAL RESEARCH

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Correction

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study